The $500M convertible offering significantly extends Celcuity's cash runway through potential FDA approval and commercialization of gedatolisib, but introduces dilution risk at a ~40% premium. Monitor the June 8 closing and any subsequent updates on the NDA review (PDUFA date not stated).
CELC drugs
CELC drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 4 $92.47entry
- T+1 · 6mo ago −4.53%α −1.93% · $88.28
- T+5 · 5mo ago −3.22%α −0.67% · $89.49
- T+20 · 4mo ago +16.74%α +18.11% · $107.95
- T+60 · 3mo ago −4.36%α −6.24% · $88.44
Price Chart
How similar events traded
Executive Summary
Celcuity priced a $500M upsized convertible senior notes offering (0.250% coupon, due 2032), increased from $400M, with an underwriter option for an additional $75M. Net proceeds of ~$484.3M (or ~$557M with over-allotment) will repay Oxford Finance debt and fund working capital, including clinical trials and potential commercialization. The conversion premium of ~40% above the last sale price signals moderate dilution risk, but the large capital raise provides a multi-year cash runway for a pre-revenue biotech awaiting FDA action on gedatolisib.
Key Financial Metrics
Key Facts
- Upsized convertible notes offering: $500M aggregate principal, increased from $400M.
- 0.250% coupon, maturing August 1, 2032; semi-annual interest payments.
- Initial conversion price ~$124.53 per share, ~40% premium above last reported sale price on June 3, 2026.
- Underwriters have 30-day option to purchase up to an additional $75M in notes for over-allotments.
- Net proceeds estimated at ~$484.3M (or ~$557M if over-allotment exercised in full).
- Proceeds to repay all outstanding obligations under Oxford Finance loan agreement; remainder for working capital, clinical trials, and potential commercialization.
- Offering expected to close June 8, 2026, subject to customary conditions.
- Company is clinical-stage, pre-revenue, with lead candidate gedatolisib in Phase 3 for HR+/HER2- breast cancer.
- Conversion premium of 40% provides some cushion against near-term dilution, but full conversion at $124.53 would add significant share count.
Financial Impact
Net proceeds of ~$484.3M (or ~$557M with over-allotment) provide substantial capital for a pre-revenue biotech with ~$4.3B market cap. Full conversion at $124.53 would add ~4.0M shares (based on $500M / $124.53), representing roughly 5-6% dilution relative to current shares outstanding (estimated from market cap and stock price). The 0.250% coupon is minimal interest expense.
Risk Factors
- Dilution risk: Full conversion of notes at $124.53 would add ~4M shares, potentially pressuring stock price.
- Execution risk: Proceeds used for clinical trials and commercialization; failure of gedatolisib to gain FDA approval would leave company with high cash burn and no revenue.
- Market risk: Convertible notes may create overhang if stock trades near conversion price, encouraging arbitrage activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306482 |
Track record
26 reports on CELC
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers